CYP3A4 and non-small cell lung carcinoma: Individualized gefitinib dosing, based on pharmacogenetic genotype and proactive monitoring of potential DDIs, with dose modifications, to counteract the impact of CYP3A4 inductions, inhibition, or phenoconversion, ensures improved clinical outcomes for patients with NSCLC.